Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Filippo Milano
Fred Hutch/University of Washington Cancer Consortium
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California San Francisco
San Francisco, California, United States
- Children'S National Medical Center
Washington D.C., District of Columbia, United States
- Case Western Reserve University
Cleveland, Ohio, United States
- Cleveland Cord Blood Center
Cleveland, Ohio, United States
- Fred Hutch/university of Washington Cancer Consortium
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 6 Oct 2022
- Primary completion
- 11 Nov 2022
- Completion
- 30 Nov 2022
- Last update posted
- 1 Jan 2025
- Registered enrollment
- 1
- Registry id
- NCT04083170
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.